INOVIO: COMP Issues Positive Opinion For Orphan Drug Designation In The EU For INO-3107
WASHINGTON (dpa-AFX) - INOVIO (INO) announced that the European Committee for Orphan Medicinal Products has provided a positive opinion on…
3,970$
-1,49%
Echtzeit-Aktienkurs Inovio Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Inovio Pharmaceuticals Inc. Aktie
Inovio Presents Data From Phase 1b Trial With INO-4201 As Ebola Booster For RVSV-ZEBOV
WASHINGTON (dpa-AFX) - Inovio (INO) said that data from a Phase 1b trial evaluating INO-4201 as an Ebola booster vaccine…
Why Shares of Inovio Pharmaceuticals Were Down Tuesday
The biotech stock, still reeling from a failed clinical trial, hit a 52-week low....…
INOVIO Reports Inducement Grant Under Inducement Plan
PLYMOUTH MEETING, Pa., April 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA…
Insiderhandel: Aufsichtsrat verkauft Aktien von Inovio Pharmaceuticals im Wert von 6.708$
Weiner, David B. - Aufsichtsrat - Tag der Transaktion: 2023-03-13...…
Inovio stock rises amid mixed trial results for cervical lesions drug; Q4 clinical updates
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Inovio Pharmaceuticals (INO) Reports Q4 Loss, Lags Revenue Estimates
Inovio (INO) delivered earnings and revenue surprises of -31.25% and 72.59%, respectively, for the quarter ended December 2022. Do the…
Inovio Pharmaceuticals (INO) Q4 2022 Earnings Call Transcript
INO earnings call for the period ending December 31, 2022....…
Why Inovio (INO) Shares Are Moving After-Hours
After falling initially in after-hours trading on Wednesday, Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are back up following the company report of worse-than-expected fourth-quarter…
Inovio Pharmaceuticals Inc. Q4 Loss decreases, but misses estimates
WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals Inc. (INO) revealed Loss for fourth quarter that decreased from the same period last year…
INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights
Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squamous intraepithelial…
Insiderhandel: Aufsichtsrat verkauft Aktien von Inovio Pharmaceuticals im Wert von 14.935$
Weiner, David B. - Aufsichtsrat - Tag der Transaktion: 2023-02-27...…
INOVIO Reports Inducement Grants Under Inducement Plan
PLYMOUTH MEETING, Pa., Feb. 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines…
INOVIO Pharma Announces Positive Results From Phase 1b Clinical Trial Evaluating INO-4201
WASHINGTON (dpa-AFX) - Biotechnology company INOVIO Pharmaceuticals, Inc. (INO) announced Thursday positive results from a Phase 1b clinical trial evaluating…
INOVIO Announces Further Reorganization, Continues Focus on Promising DNA Candidates
read more...…
Inovio in strategic reorganization; 11% headcount reduction
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
INOVIO Announces 11% Headcount Reduction
WASHINGTON (dpa-AFX) - INOVIO (INO) announced a strategic reorganization, which is expected to provide annual savings of approximately $4.3 million…
Inovio Pharmaceuticals to Cut Full-Time Staff by 11% >INO
Inovio Pharmaceuticals to Cut Full-Time Staff by 11% >INO...…
Form 8-K INOVIO PHARMACEUTICALS, For: Jan 18
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Inovio ends development of candidates for Lassa fever and Middle East Respiratory Syndrome
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
INOVIO Provides an Update on Lassa Fever and MERS Programs
PLYMOUTH MEETING, Pa., Nov. 17, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA…
Inovio Pharmaceuticals stock rises on Q3 profit beat, raised cash runway guidance
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Inovio Pharmaceuticals (INO) Q3 2022 Earnings Call Transcript
INO earnings call for the period ending September 30, 2022....…
Inovio Pharmaceuticals (INO) Reports Q3 Loss, Tops Revenue Estimates
Inovio (INO) delivered earnings and revenue surprises of 48.28% and 3,880%, respectively, for the quarter ended September 2022. Do the…
Inovio Pharmaceuticals Inc. Q3 Loss decreases, beats estimates
WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals Inc. (INO) revealed Loss for third quarter that decreased from the same period last year…
Form 10-Q INOVIO PHARMACEUTICALS, For: Sep 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Inovio Pharmaceuticals stops development of COVID-19 booster shot candidate
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800
PLYMOUTH MEETING, Pa., Oct. 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines…
Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Inovio Pharma Highlights Early Data From Experimental Drug For Respiratory Tract Disease
read more...…
INOVIO Reports Positive Interim Phase 1/2 Trial Results For INO-3107 For Respiratory Papillomatosis
WASHINGTON (dpa-AFX) - Biotechnology company Inovio Pharmaceuticals Inc. (INO) announced Thursday positive interim results from an ongoing Phase 1/2 clinical…